| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 04/08/2004 | US20040067232 Methods for treating autoimmune diseases in a subject and in vitro diagnostic assays |
| 04/08/2004 | DE10244810A1 Neue Morpholin-überbrückte Indazolderivate New morpholine-bridged indazole derivatives |
| 04/08/2004 | CA2523618A1 Methods for promoting dopaminergic neuronal development by using ng4a-subfamily and wnt-ligands |
| 04/08/2004 | CA2500420A1 Anti-neurodegenerative agents |
| 04/08/2004 | CA2500415A1 Amino acid composition for improving central nervous function |
| 04/08/2004 | CA2500228A1 [1,2,4]-triazolo[1,5-c]pyrimidine derivative |
| 04/08/2004 | CA2500198A1 Combined use of methylphenidate and melatonin for treating attention-deficit hyperactive disorder |
| 04/08/2004 | CA2500189A1 Therapies for chronic inflammatory demyelinating polyneuropathy using interferon-.beta. |
| 04/08/2004 | CA2500117A1 Process for preparing haloalkyl pyrimidines |
| 04/08/2004 | CA2500115A1 Heterocyclic substituted piperazines for the treatment of schizophrenia |
| 04/08/2004 | CA2500109A1 Compounds for the treatment of alzheimer's disease |
| 04/08/2004 | CA2499497A1 Substituted pyrimidines |
| 04/07/2004 | EP1405906A1 Schwann cells originating in myeloid interstitial cells |
| 04/07/2004 | EP1405639A1 Use of sodium channel blocking compounds and aspirin in manufacturing drugs for producing synergistic analgesic effect in mammals |
| 04/07/2004 | EP1405638A1 Medicinal composition for treatment of interstitial cystitis |
| 04/07/2004 | EP1405083A2 Natural ligand of gpcr chemr23 and uses thereof |
| 04/07/2004 | EP1404876A2 Interferon alpha-14 polymorphism |
| 04/07/2004 | EP1404870A2 Function and application of tob gene in central nervous system of mammal |
| 04/07/2004 | EP1404864A2 Regulation of neuronal function through metabotropic glutamate receptor signaling pathways |
| 04/07/2004 | EP1404831A2 Type 2 cytokine receptor and nucleic acids encoding same |
| 04/07/2004 | EP1404812A1 Dopaminergic neurons and proliferation-competent precursor cells for treating parkinson's disease |
| 04/07/2004 | EP1404718A2 Inhibitors of memapsin 2 and use thereof |
| 04/07/2004 | EP1404714A2 Nuclear hormone receptor ligand binding domain |
| 04/07/2004 | EP1404710A2 Identification of ses-3 (spr-5) in c. elegans and the uses of the same |
| 04/07/2004 | EP1404703A2 G-protein coupled receptors |
| 04/07/2004 | EP1404682A1 Method of inhibiting ptp 1b and/or t-cell ptp and/or other ptpases with an asp residue at position 48 |
| 04/07/2004 | EP1404679A2 (hetero)aryl substituted benzofurans as 5-ht ligands |
| 04/07/2004 | EP1404677A1 Imidazotriazines for use as phosphodiesterase inhibitors |
| 04/07/2004 | EP1404674A2 Quinuclidine-substituted heteroaromatic compounds as ligands at nicotinic acetylcholine receptors |
| 04/07/2004 | EP1404672A1 Tyrosine kinase inhibitors |
| 04/07/2004 | EP1404671A1 Macrocycles useful in the treatment of alzheimer's disease |
| 04/07/2004 | EP1404669A2 Heterocyclic substituted pyrazoles as inhibitors of src and other protein kinases |
| 04/07/2004 | EP1404667A1 Piperidine derivatives useful as modulators of chemokine receptor activity |
| 04/07/2004 | EP1404664A1 Aminediols for the treatment of alzheimer's disease |
| 04/07/2004 | EP1404656A1 Benzimidazole derivatives for treating microglia-activation associated diseases such as inflammatory, allergic, infectious or autoimmune diseases |
| 04/07/2004 | EP1404650A1 Carboxamide-substituted phenylurea derivatives and method for production thereof as medicaments |
| 04/07/2004 | EP1404641A1 Crystalline form of a phenylethanolamine, the preparation thereof and pharmaceutical compositions comprising the same |
| 04/07/2004 | EP1404367A2 Use of polyclonal anti-hiv goat serum as a therapeutic agent |
| 04/07/2004 | EP1404350A2 Proteins associated with cell growth, differentiation, and death |
| 04/07/2004 | EP1404344A2 Bone anabolic compounds and methods of use |
| 04/07/2004 | EP1404343A2 Therapeutic combinations for the treatment of hormone deficiencies |
| 04/07/2004 | EP1404342A1 Treatment of psychotic disorders comprising co-therapy with anticonvulsant derivatives and atypical antipsychotics |
| 04/07/2004 | EP1404341A1 Active substance combination for medicamentous therapy of nicotine dependency |
| 04/07/2004 | EP1404340A1 Naphtothiazine positive allosteric ampa receptor modulators (paarm) |
| 04/07/2004 | EP1404339A2 Method for treating fibrotic diseases or other indications vi |
| 04/07/2004 | EP1404337A2 QUINAZOLINE AND PYRIDO 2,3-d]PYRIMIDINE INHIBITORS OF PHOSPHODIESTERASE (PDE) 7 |
| 04/07/2004 | EP1404333A1 Oxymorphone controlled release formulations |
| 04/07/2004 | EP1404332A1 Methods of making sustained release formulations of oxymorphone related applications |
| 04/07/2004 | EP1404331A1 Sustained release formulations of oxymorphone |
| 04/07/2004 | EP1404330A1 Substituted 8-arylquinoline pde4 inhibitors |
| 04/07/2004 | EP1404328A1 Alpha-hydroxyamide statine derivatives for the treatment of alzheimer's disease |
| 04/07/2004 | EP1404326A2 Method of treating parkinson's disease |
| 04/07/2004 | EP1404325A2 Method for treating nerve injury caused by surgery |
| 04/07/2004 | EP1404324A2 Prodrugs of gaba analogs, compositions and uses thereof |
| 04/07/2004 | EP1404323A1 Use of methylnaltrexone to treat immune suppression |
| 04/07/2004 | EP1404321A1 1-alkyl-2-aryl-benzimidazole derivatives, their use for producing medicaments and pharmaceutical preparations containing said derivatives |
| 04/07/2004 | EP1404320A2 A pharmaceutical composition comprising a nicotinic receptor partial antagonist and an antiemetic agent for modulating cholinergic function |
| 04/07/2004 | EP1404317A1 5-halo-tryptamine derivatives used as ligands of the 5-ht 6? and/or 5-ht 7? serotonin receptors |
| 04/07/2004 | EP1404316A1 Cycloalkylpyrrole-3-carboxylic acid derivatives and heterocycloalkylpyrrole-3-carboxylic acid derivatives as gaba-a receptor ligands |
| 04/07/2004 | EP1404315A1 Synergistic compositions of n-acylhomoserine lactones and 4-quinolones |
| 04/07/2004 | EP1404314A1 Aerosol formulations of delta 8 tetrahydrocannabinol |
| 04/07/2004 | EP1404312A1 Carbamate compounds for use in the treatment of pain |
| 04/07/2004 | EP1404310A1 Orally administered dosage forms of gaba analog prodrugs having reduced toxicity |
| 04/07/2004 | EP1404308A1 Treatment of disorders secondary to organic impairments |
| 04/07/2004 | EP1404306A1 A coated nicotine-containing chewing gum, manufacture and use thereof |
| 04/07/2004 | EP1404302A1 Pharmaceutical compositions of adsorbates of amorphous drug |
| 04/07/2004 | EP1226133B1 N-SUBSTITUTED 3-AMINO-2,2-DI-C-ALKYL-1,4-BUTYROLACTONES AND 1,4-THIOBUTYROLACTONES FOR USE AS PROMOTER OF $g(g)-AMINOBUTYRIC ACID ACTIVITY AND FOR TREATING NERVOUS DISORDERS AND PREPARATION METHOD |
| 04/07/2004 | EP1185272B1 Novel use of 1-[4-(5-cyanoindol-3yl)butyl]-4-(2-carbamoylbenzofuran-5-yl)piperazine and its physiological acceptable salts for the treatment of bipolar disorders and mania |
| 04/07/2004 | EP1150991B1 Compositions for treating inflammatory response |
| 04/07/2004 | EP1149087B1 Piperidine, tetrahydropyridine and piperazine derivatives, their preparation and use |
| 04/07/2004 | EP0836511B1 Device for transdermal electrotransport delivery of fentanyl and sufentanil |
| 04/07/2004 | EP0787148B1 Al-1 neurotrophic factor, a ligand for an eph-related tyrosine kinase receptor |
| 04/07/2004 | EP0720483B1 Use of growth hormone in the manufacture of a medicament for the treatment of ischaemic brain damage and dementia |
| 04/07/2004 | CN1487939A Amido ether substituted imidazoquinolines |
| 04/07/2004 | CN1487933A Pyrazole compounds useful as protein kinase inhibitors |
| 04/07/2004 | CN1487932A New process for the preparation of the anti-migraine drug |
| 04/07/2004 | CN1487923A Process for the preparation of (3-cyano-1H-indol-7-yl) (4-(4-fluorophenethyl)piperazin-1-yl)-methanone and salts thereof |
| 04/07/2004 | CN1487840A Molecular antigen array |
| 04/07/2004 | CN1487838A Molecular antigen array |
| 04/07/2004 | CN1487836A Effects of glucagon-like peptide-1 (7-36) on antro-pyloro-duodenal motility |
| 04/07/2004 | CN1487831A Tetrahydro-(benzo or thieno)-azepine-pyrazine and triazine derivatives as mGluR1 antagonists |
| 04/07/2004 | CN1487830A Use of 6-dimethylaminomethy1-1-pheny1-cyclohexane compounds for treating urinary incontinence |
| 04/07/2004 | CN1487827A Process for preparing non-hygroscopic sodium valproate composition |
| 04/07/2004 | CN1487085A Conotoxin MVÔàí A and Trx fusion protein and its expression and application |
| 04/07/2004 | CN1486987A COmpound Bajisu A and its prepn and use |
| 04/07/2004 | CN1486973A Ethyl methyl 3-[(1s)-1-(dimethylamino) ethyl] phenyl carbamate and its prepn and medicine use |
| 04/07/2004 | CN1486725A Chinese medicine prepn for treating epilepsy and its use |
| 04/07/2004 | CN1486693A Prepn and product of oxiracetam powder for injection |
| 04/07/2004 | CN1144800C Indolyl derivatives as 5-hydroxytryptamine medicine |
| 04/07/2004 | CN1144799C N-(iminomethyl) amine derivatives, their preparation, their use as medicines and medical compositions containing the same |
| 04/07/2004 | CN1144794C Benzoxazine and benzothiazine derivatives and their application in medicines |
| 04/07/2004 | CN1144791C Triazole compounds and its application as dopamine-D3-ligands |
| 04/07/2004 | CN1144790C Telmisartan polymorphs, producing process thereof and use in prepn. of pharmaceutical composition thereof |
| 04/07/2004 | CN1144789C Pyrrolidine and piperidine derivatives, producing process and application thereof |
| 04/07/2004 | CN1144787C Aryl fused azapolycyclic compounds |
| 04/07/2004 | CN1144784C Diphenyl alkyl-tetrahydropyridines, process for their preparation, and pharmaceutical composition containing them |
| 04/07/2004 | CN1144783C Prostaglandin derivative |
| 04/07/2004 | CN1144588C 睡眠诱发剂 Sleep-inducing agent |
| 04/06/2004 | US6717030 Diploid animal cell for use in the treatment of drug addiction, epilepsey, withdrawal syndrome and muscle spasm |
| 04/06/2004 | US6717012 Such as alpha-phenyl-n-(7-tert-butoxycarbonylamino-3,5-dimethyladamantane)nitrone for treatment of neurological/ inflammatory diorders, and aging, which result from the overproduction of nitric oxide |